Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of BOS172767 Enantiomers in Healthy Subjects
NCT04514237Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BOS172767 enantiomer E1 or E2 in psoriasis and autoimmune diseases (2 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Relative bioavailability of E1 versus E2, Number of participants with any treatment-emergent adverse event at Day 59 and 6 more. Started Sep 2019; status: completed.
02
Drugs
BOS172767 enantiomer E1 or E2
03
Conditions
psoriasisautoimmune diseases
Beyond the preview
Go deeper on NCT04514237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514237.